{"id":"NCT02180165","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)","officialTitle":"A Randomized, Comparative, Open-label Study to Assess the Safety and Efficacy of MK-5592 Compared With Voriconazole in Japanese Subjects With Deep-seated Fungal Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-07-29","primaryCompletion":"2018-01-24","completion":"2018-01-24","firstPosted":"2014-07-02","resultsPosted":"2019-01-11","lastUpdate":"2021-01-28"},"enrollment":116,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Aspergillosis"],"interventions":[{"type":"DRUG","name":"Posaconazole","otherNames":[]},{"type":"DRUG","name":"Voriconazole","otherNames":[]}],"arms":[{"label":"Cohort 1: Posaconazole","type":"EXPERIMENTAL"},{"label":"Cohort 1: Voriconazole","type":"ACTIVE_COMPARATOR"},{"label":"Cohort 2: Posaconazole","type":"EXPERIMENTAL"},{"label":"Cohort 2: Voriconazole","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this study is to assess and compare the safety of posaconazole with voriconazole in Japanese participants with aspergillosis.","primaryOutcome":{"measure":"Number of Participants With an Adverse Event","timeFrame":"Up to approximately Day 98","effectByArm":[{"arm":"Cohort 1: Posaconazole","deltaMin":15,"sd":null},{"arm":"Cohort 1: Voriconazole","deltaMin":6,"sd":null},{"arm":"Cohort 2: Posaconazole","deltaMin":57,"sd":null},{"arm":"Cohort 2: Voriconazole","deltaMin":27,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":18},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":15},"commonTop":["Pyrexia","Hepatic function abnormal","Constipation","Hypokalaemia","Photophobia"]}}